Erratum: Activation of GPR55 receptors exacerbates oxLDL-induced lipid accumulation and inflammatory responses, while reducing cholesterol efflux from human macrophages (PLoS ONE 10 5 (e0126839) (DOI:10.1371/journal.pone.0126839));Activation of GPR55 receptors exacerbates oxLDL-induced lipid accumulation and inflammatory responses, while reducing cholesterol efflux from human macrophages

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Lanuti, Mirko ^a   Talamonti, Emanuela ^a,b   Maccarrone, Mauro ^a,b   Chiurchiú, Valerio ^a,b  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; CANNABIDIOL; CD36 ANTIGEN; CELL PROTEIN; GELATINASE B; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEIN GPR55; UNCLASSIFIED DRUG; 4 (6 ISOPROPENYL 3 METHYL 2 CYCLOHEXENYL) 5 METHYLRESORCINOL; CHOLESTEROL; CYCLOHEXANE DERIVATIVE; CYTOKINE; FAT DROPLET; G PROTEIN COUPLED RECEPTOR; GPR55 PROTEIN, HUMAN; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN; MMP9 PROTEIN, HUMAN; RESORCINOL DERIVATIVE; TRANSCRIPTION FACTOR NFAT;

ARTICLE; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; FOAM CELL; HUMAN; HUMAN CELL; INFLAMMATION; LIPID STORAGE; MACROPHAGE; PHARMACOLOGICAL BLOCKING; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION; AGONISTS; ATHEROSCLEROSIS; CELL LINE; GENE EXPRESSION; GENETICS; IMMUNOLOGY; LIPID METABOLISM; METABOLISM; PHYSIOLOGY; SECRETION (PROCESS);

ATHEROSCLEROSIS; CELL LINE; CHOLESTEROL; CYCLOHEXANES; CYTOKINES; FOAM CELLS; GENE EXPRESSION; HUMANS; LIPID DROPLETS; LIPID METABOLISM; LIPOPOLYSACCHARIDES; LIPOPROTEINS, LDL; MATRIX METALLOPROTEINASE 9; NFATC TRANSCRIPTION FACTORS; RECEPTORS, G-PROTEIN-COUPLED; RESORCINOLS;

EID: 84929340245     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0131850     Document Type: Erratum

References (57)

1. Collot-Teixeira S, Martin J, McDermott-Roe C, Poston R, McGregor JL (2007) CD36 and macrophages in atherosclerosis. Cardiovasc Res 75: 468-77. PMID: 17442283
2. Xu M, Zhou H, Tan KC, Guo R, Shiu SW, Wong Y (2009) ABCG1 mediated oxidized LDL-derived oxysterol efflux from macrophages. Biochem Biophys Res Commun 390: 1349-54. doi: 10.1016/j.bbrc.2009.10.152 PMID: 19895785
3. de La Llera-Moya M, Connelly MA, Drazul D, Klein SM, Favari E, Yancey PG, et al. (2001) Scavenger receptor class B type I affects cholesterol homeostasis by magnifying cholesterol flux between cells and HDL. J Lipid Res. 42: 1969-78. PMID: 11734569
4. Lipsky RH, Eckert DM, Tang Y, Ockenhouse CF (1997) The carboxyl-terminal cytoplasmic domain of CD36 is required for oxidized low-density lipoprotein modulation of NF-kappaB activity by tumor necrosis factor-alpha. Recept Signal Transduct 7: 1-11. PMID: 9285527
5. Han CY, Park SY, Pak YK (2000) Role of endocytosis in the transactivation of nuclear factor-kappaB by oxidized low-density lipoprotein. Biochem J 350: 829-37. PMID: 10970799
6. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM (1998) PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93: 241-52. PMID: 9568716
7. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM (1998) Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 93: 229-40. PMID: 9568715
8. Bełtowski J, Wójcicka G, Jamroz-Wisniewska A (2009) Adverse effects of statins - mechanisms and consequences. Curr Drug Saf 4: 209-28. PMID: 19534648
9. Dol-Gleizes F, Paumelle R, Visentin V, Marés AM, Desitter P, Hennuyer N, et al. (2009) Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 29: 12-8. doi: 10.1161/ATVBAHA.108.168757 PMID: 18845788
10. Mach F, Steffens S (2008) The role of the endocannabinoid system in atherosclerosis. J Neuroendocrinol 20: 53-7. doi: 10.1111/j.1365-2826.2008.01685.x PMID: 18426500
11. Chiurchiú V, Lanuti M, Catanzaro G, Fezza F, Rapino C, Maccarrone M (2014) Detailed characterization of the endocannabinoid system in human macrophages and foam cells, and anti-inflammatory role of type-2 cannabinoid receptor. Atherosclerosis 233: 55-63. doi: 10.1016/j.atherosclerosis.2013.12.042 PMID: 24529123
12. Hoyer FF, Steinmetz M, Zimmer S, Becker A, Lütjohann D, Buchalla R, et al. (2011) Atheroprotection via cannabinoid receptor-2 is mediated by circulating and vascular cells in vivo. J Mol Cell Cardiol 51: 1007-14. doi: 10.1016/j.yjmcc.2011.08.008 PMID: 21884703
13. Delsing DJ, Leijten FP, Arts K, van Eenennaam H, Garritsen A, Gijbels MJ, et al. (2011) Cannabinoid Receptor 2 Deficiency in Haematopoietic cells Aggravates Early Atherosclerosis in LDL Receptor Deficient Mice. Open Cardiovasc Med J 5: 15-21. doi: 10.2174/1874192401105010015 PMID: 21660251
14. Netherland CD, Pickle TG, Bales A, Thewke DP (2010) Cannabinoid receptor type 2 (CB2) deficiency alters atherosclerotic lesion formation in hyperlipidemic Ldlr-null mice. Atherosclerosis 213: 102-8. doi: 10.1016/j.atherosclerosis.2010.07.060 PMID: 20846652
15. Steffens S, Pacher P (2012) Targeting cannabinoid receptor CB(2) in cardiovascular disorders: promises and controversies. Br J Pharmacol 167: 313-23. doi: 10.1111/j.1476-5381.2012.02042.x PMID: 22612332
16. Pacher P (2009) Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns. Arterioscler Thromb Vasc Biol 29: 7-9. doi: 10.1161/ATVBAHA.108.178129 PMID: 19092136
17. Sharir H, Abood ME (2010) Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol Ther 126: 301-13. doi: 10.1016/j.pharmthera.2010.02.004 PMID: 20298715
18. Whyte LS, Ryberg E, Sims NA, Ridge SA, Mackie K, Greasley PJ, et al. (2009) The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci U S A 106: 16511-6. doi: 10.1073/pnas.0902743106 PMID: 19805329
19. Staton PC, Hatcher JP, Walker DJ, Morrison AD, Shapland EM, Hughes JP, et al. (2008) The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain 139: 25-36.
20. Sylantyev S, Jensen TP, Ross RA, Rusakov DA (2013) Cannabinoid- and lysophosphatidylinositolsensitive receptor GPR55 boosts neurotransmitter release at central synapses. Proc Natl Acad Sci U S A 110: 5193-8. doi: 10.1073/pnas.1211204110 PMID: 23472002
21. Balenga NA, Aflaki E, Kargl J, Platzer W, Schröder R, Blättermann S, et al. (2011) GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils. Cell Res 21: 1452-69. doi: 10.1038/cr.2011.60 PMID: 21467997
22. McHugh D, Ross RA "Endogenous cannabinoids and neutrophil chemotaxis", Vitam Horm., vol. 81, pp. 337-65, 2009. doi: 10.1016/S0083-6729(09)81013-3 PMID: 19647118
23. Cantarella G, Scollo M, Lempereur L, Saccani-Jotti G, Basile F, Bernardini R (2011) Endocannabinoids inhibit release of nerve growth factor by inflammation-activated mast cells. Biochem Pharmacol 82: 380-8. doi: 10.1016/j.bcp.2011.05.004 PMID: 21601562
24. Waldeck-Weiermair M, Zoratti C, Osibow K, Balenga N, Goessnitzer E, Waldhoaer M, et al. Integrin clustering enables anandamide-induced Ca2+ signaling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression. J Cell Sci. 121: 1704-17. doi: 10.1242/jcs.020958 PMID: 18445684
25. Zhang X, Maor Y, Wang JF, Kunos G, Groopman JE (2010) Endocannabinoid-like N-arachidonoyl serine is a novel pro-angiogenic mediator. Br J Pharmacol 160: 1583-94. doi: 10.1111/j.1476-5381.2010.00841.x PMID: 20649563
26. Chiurchiú V, Izzi V, D'Aquilio F, Carotenuto F, Di Nardo P, Baldini PM (2008) Brain Natriuretic Peptide (BNP) regulates the production of inflammatory mediators in human THP-1 macrophages. Regul Pept 148: 26-32. doi: 10.1016/j.regpep.2008.02.009 PMID: 18410972
27. Izzi V, Chiurchiú V, D'Aquilio F, Martino A, Tresoldi I, Modesti M, et al. (2008) Endomorphin-1 inhibits the activation and the development of a hyporesponsive-like phenotype in lipopolysaccharide-stimulated THP-1 monocytes. Int J Immunopathol Pharmacol 21: 833-43. PMID: 19144269
28. Izzi V, Chiurchiú V, D'Aquilio F, Palumbo C, Tresoldi I, Modesti A, et al. (2009) Differential effects of malignant mesothelioma cells on THP-1 monocytes and macrophages. Int J Oncol 34: 543-50. PMID: 19148491
29. Chiurchiú V, Izzi V, D'Aquilio F, Vismara D, Carotenuto F, Catanzaro G, et al. (2011) Endomorphin-1 prevents lipid accumulation via CD36 down-regulation and modulates cytokines release from human lipid-laden macrophages. Peptides 32: 80-5. doi: 10.1016/j.peptides.2010.09.024 PMID: 20932867
30. Chiurchiú V, Cencioni MT, Bisicchia E, De Bardi M, Gasperini C (2013) Distinct modulation of human myeloid and plasmacytoid dendritic cells by anandamide in multiple sclerosis. Ann Neurol 73: 626-36. doi: 10.1002/ana.23875 PMID: 23447381
31. Cencioni MT, Chiurchiú V, Catanzaro G, Borsellino G, Bernardi G, Battistini L, et al. (2010) Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. PLoS One 5: e8688. doi: 10.1371/journal.pone.0008688 PMID: 20098669
32. Chiurchiú V, Lanuti M, De Bardi M, Battistini L, Maccarrone M (2015) The differential characterization of GPR55 receptor in human peripheral blood reveals a distinctive expression in monocytes and NK cells and a proinflammatory role in these innate cells. Int Immunol 27: 153-60. doi: 10.1093/intimm/dxu097 PMID: 25344934
33. Li K, Fichna J, Schicho R, Saur D, Bashashati M, Mackie K, et al. (2013) A role for O-1602 and G protein-coupled receptor GPR55 in the control of colonic motility in mice. Neuropharmacol 71: 255-63.
34. McKillop AM, Moran BM, Abdel-Wahab YH, Flatt PR (2013) Evaluation of the insulin releasing and antihyperglycaemic activities of GPR55 lipid agonists using clonal beta-cells, isolated pancreatic islets and mice. Br J Pharmacol 170: 978-90. doi: 10.1111/bph.12356 PMID: 23992544
35. Henstridge CM, Balenga NA, Ford LA, Ross RA, Waldhoer M, Irving AJ (2009) The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation. FASEB J 23: 183-93. doi: 10.1096/fj.08-108670 PMID: 18757503
36. Fric J, Zelante T, Wong AY, Mertes A, Yu HB, Ricciardi-Castagnoli P (2012) NFAT control of innate immunity. Blood 120: 1380-9. doi: 10.1182/blood-2012-02-404475 PMID: 22611159
37. Libby P (2002) Inflammation in atherosclerosis. Nature 420: 868-74. PMID: 12490960
38. Lipina C, Stretton C, Hastings S, Hundal JS, Mackie K, Irving AJ, et al. (2009) Regulation of MAP kinase-directed mitogenic and protein kinase B-mediated signaling by cannabinoid receptor type 1 in skeletal muscle cells. Diabetes 59: 375-85. doi: 10.2337/db09-0979 PMID: 19933999
39. Després JP, Golay A, Sjöström L (2005) Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353: 2121-34. PMID: 16291982
40. Costet P, Luo Y, Wang N, Tall AR (2000) Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem 275: 28240-5. PMID: 10858438
41. Sabol SL, Brewer HB Jr, Santamarina-Fojo S (2005) The human ABCG1 gene: identification of LXR response elements that modulate expression in macrophages and liver. J Lipid Res 46: 2151-67. PMID: 16024918
42. Maini RN, Elliott MJ, Brennan FM, Feldmann M (1995) Beneficial effects of tumour necrosis factoralpha (TNF-alpha) blockade in rheumatoid arthritis (RA). Clin Exp Immunol 101: 207-12. PMID: 7648705
43. Boyle JJ, Weissberg PL, Bennett MR (2003) Tumor necrosis factor-alpha promotes macrophage-induced vascular smooth muscle cell apoptosis by direct and autocrine mechanisms. Arterioscler Thromb Vasc Biol 23: 1553-8. PMID: 12869351
44. Li Y, Gerbod-Giannone MC, Seitz H, Cui D, Thorp E, Tall AR, et al. (2005) Cholesterol-induced apoptotic macrophages elicit an inflammatory response in phagocytes, which is partially attenuated by the Mer receptor. J Biol Chem 281: 6707-17. PMID: 16380374
45. Ohta H, Wada H, Niwa T, Kirii H, Iwamoto N, Fujii H, et al. (2005) Disruption of tumor necrosis factoralpha gene diminishes the development of atherosclerosis in ApoE-deficient mice. Atherosclerosis 180: 11-7. PMID: 15823270
46. Arjuman A, Chandra NC (2013) Effect of IL-10 on LOX-1 expression, signalling and functional activity: an atheroprotective response. Diab Vasc Dis Res 10: 442-51. doi: 10.1177/1479164113489042 PMID: 23811604
47. Halvorsen B, Holm S, Yndestad A, Scholz H, Sagen EL, Nebb H, et al. (2014) Interleukin-10 increases reverse cholesterol transport in macrophages through its bidirectional interaction with liver X receptor α. Biochem Biophys Res Commun 450: 1525-30. doi: 10.1016/j.bbrc.2014.07.036 PMID: 25035925
48. Massaro M, Zampolli A, Scoditti E, Carluccio MA, Storelli C, Distante A, et al. (2010) Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angiogenic actions possibly contributing to plaque stability. Cardiovasc Res 86: 311-20. doi: 10.1093/cvr/cvp375 PMID: 19946014
49. Ross RA (2009) The enigmatic pharmacology of GPR55. Trends Pharmacol Sci 30: 156-163. doi: 10.1016/j.tips.2008.12.004 PMID: 19233486
50. Heynen-Genel S, Dahl R, Shi S, Milan L, Hariharan S, Sergienko E, et al. (2010) Screening for Selective Ligands for GPR55 - Antagonists. Probe Reports from the NIH Molecular Libraries Program [Internet].
51. Heynen-Genel S, Dahl R, Shi S, Milan L, Hariharan S, Bravo Y, et al. (2010) Screening for Selective Ligands for GPR55 - Agonists. Probe Reports from the NIH Molecular Libraries Program [Internet].
52. Simcocks AC, O'Keefe L, Jenkin KA, Mathai ML, Hryciw DH, McAinch AJ (2013) A potential role for GPR55 in the regulation of energy homeostasis. Drug Discov Today 19: 1145-51. doi: 10.1016/j.drudis.2013.12.005 PMID: 24370891
53. Díaz-Arteaga A, Vázquez MJ, Vazquez-Martínez R, Pulido MR, Suarez J, Velásquez DA, et al. (2012) The atypical cannabinoid O-1602 stimulates food intake and adiposity in rats. Diabetes Obes Metab 14: 234-43. doi: 10.1111/j.1463-1326.2011.01515.x PMID: 21981246
54. Moreno-Navarrete JM1, Catalán V, Whyte L, Díaz-Arteaga A, Vázquez-Martínez R, Rotellar F, et al. (2012) The L-α-lysophosphatidylinositol/GPR55 system and its potential role in human obesity. Diabetes 61: 281-91. doi: 10.2337/db11-0649 PMID: 22179809
55. Romero-Zerbo SY, Rafacho A, Díaz-Arteaga A, Suárez J, Quesada I, Imbernon M, et al. (2011) A role for the putative cannabinoid receptor GPR55 in the islets of Langerhans. J Endocrinol 211: 177-85. doi: 10.1530/JOE-11-0166 PMID: 21885477
56. Kargl J, Brown AJ, Andersen L, Dorn G, Schicho R, Waldhoer M, et al. (2013) A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function. J Pharmacol Exp Ther 346: 54-66. doi: 10.1124/jpet.113.204180 PMID: 23639801
57. Bondarenko A, Waldeck-Weiermair M, Naghdi S, Poteser M, Malli R, Graier WF (2010) GPR55- dependent and -independent ion signalling in response to lysophosphatidylinositol in endothelial cells. Br J Pharmacol 161: 308-20. doi: 10.1111/j.1476-5381.2010.00744.x PMID: 20735417